BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36747758)

  • 1. Fructose Induced KHK-C Increases ER Stress and Modulates Hepatic Transcriptome to Drive Liver Disease in Diet-Induced and Genetic Models of NAFLD.
    Park SH; Helsley RN; Fadhul T; Willoughby JLS; Noetzli L; Tu HC; Solheim MH; Fujisaka S; Pan H; Dreyfuss JM; Bons J; Rose J; King CD; Schilling B; Lusis AJ; Pan C; Gupta M; Kulkarni RN; Fitzgerald K; Kern PA; Divanovic S; Kahn CR; Softic S
    bioRxiv; 2023 Jan; ():. PubMed ID: 36747758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fructose induced KHK-C can increase ER stress independent of its effect on lipogenesis to drive liver disease in diet-induced and genetic models of NAFLD.
    Park SH; Helsley RN; Fadhul T; Willoughby JLS; Noetzli L; Tu HC; Solheim MH; Fujisaka S; Pan H; Dreyfuss JM; Bons J; Rose J; King CD; Schilling B; Lusis AJ; Pan C; Gupta M; Kulkarni RN; Fitzgerald K; Kern PA; Divanovic S; Kahn CR; Softic S
    Metabolism; 2023 Aug; 145():155591. PubMed ID: 37230214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketohexokinase-C regulates global protein acetylation to decrease carnitine palmitoyltransferase 1a-mediated fatty acid oxidation.
    Helsley RN; Park SH; Vekaria HJ; Sullivan PG; Conroy LR; Sun RC; Romero MDM; Herrero L; Bons J; King CD; Rose J; Meyer JG; Schilling B; Kahn CR; Softic S
    J Hepatol; 2023 Jul; 79(1):25-42. PubMed ID: 36822479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fructose and hepatic insulin resistance.
    Softic S; Stanhope KL; Boucher J; Divanovic S; Lanaspa MA; Johnson RJ; Kahn CR
    Crit Rev Clin Lab Sci; 2020 Aug; 57(5):308-322. PubMed ID: 31935149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis.
    Shepherd EL; Saborano R; Northall E; Matsuda K; Ogino H; Yashiro H; Pickens J; Feaver RE; Cole BK; Hoang SA; Lawson MJ; Olson M; Figler RA; Reardon JE; Nishigaki N; Wamhoff BR; Günther UL; Hirschfield G; Erion DM; Lalor PF
    JHEP Rep; 2021 Apr; 3(2):100217. PubMed ID: 33490936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction.
    Gutierrez JA; Liu W; Perez S; Xing G; Sonnenberg G; Kou K; Blatnik M; Allen R; Weng Y; Vera NB; Chidsey K; Bergman A; Somayaji V; Crowley C; Clasquin MF; Nigam A; Fulham MA; Erion DM; Ross TT; Esler WP; Magee TV; Pfefferkorn JA; Bence KK; Birnbaum MJ; Tesz GJ
    Mol Metab; 2021 Jun; 48():101196. PubMed ID: 33667726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated omics analysis for characterization of the contribution of high fructose corn syrup to non-alcoholic fatty liver disease in obesity.
    Papadopoulos G; Legaki AI; Georgila K; Vorkas P; Giannousi E; Stamatakis G; Moustakas II; Petrocheilou M; Pyrina I; Gercken B; Kassi E; Chavakis T; Pateras IS; Panayotou G; Gika H; Samiotaki M; Eliopoulos AG; Chatzigeorgiou A
    Metabolism; 2023 Jul; 144():155552. PubMed ID: 36996933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketohexokinase knockout mice, a model for essential fructosuria, exhibit altered fructose metabolism and are protected from diet-induced metabolic defects.
    Miller CO; Yang X; Lu K; Cao J; Herath K; Rosahl TW; Askew R; Pavlovic G; Zhou G; Li C; Akiyama TE
    Am J Physiol Endocrinol Metab; 2018 Sep; 315(3):E386-E393. PubMed ID: 29870677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial.
    Kazierad DJ; Chidsey K; Somayaji VR; Bergman AJ; Birnbaum MJ; Calle RA
    Med; 2021 Jul; 2(7):800-813.e3. PubMed ID: 35590219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease.
    Liu C; Zhou B; Meng M; Zhao W; Wang D; Yuan Y; Zheng Y; Qiu J; Li Y; Li G; Xiong X; Bian H; Zhang H; Wang H; Ma X; Hu C; Xu L; Lu Y
    J Hepatol; 2021 Jul; 75(1):150-162. PubMed ID: 33548387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adiponectin resistance and proinflammatory changes in the visceral adipose tissue induced by fructose consumption via ketohexokinase-dependent pathway.
    Marek G; Pannu V; Shanmugham P; Pancione B; Mascia D; Crosson S; Ishimoto T; Sautin YY
    Diabetes; 2015 Feb; 64(2):508-18. PubMed ID: 25187370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Michaelis-like complex of mouse ketohexokinase isoform C.
    Gasper WC; Gardner S; Ross A; Oppelt SA; Allen KN; Tolan DR
    Acta Crystallogr D Struct Biol; 2024 Jun; 80(Pt 6):377-385. PubMed ID: 38805243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bicyclol alleviates high-fat diet-induced hepatic ER stress- and autophagy-associated non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in mice.
    Jia S; Jin L; Cheng X; Wu J; Yao X; Shao J; Zhang C; Cen D; Cheng B; Wang J; Chen L; Yao X
    Drug Dev Ind Pharm; 2022 Jun; 48(6):247-254. PubMed ID: 35875932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structures of human and mouse ketohexokinase provide a structural basis for species- and isoform-selective inhibitor design.
    Ebenhoch R; Bauer M; Romig H; Gottschling D; Kley JT; Heine N; Weber A; Uphues I; Nar H; Pautsch A
    Acta Crystallogr D Struct Biol; 2023 Oct; 79(Pt 10):871-880. PubMed ID: 37712434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling.
    Softic S; Gupta MK; Wang GX; Fujisaka S; O'Neill BT; Rao TN; Willoughby J; Harbison C; Fitzgerald K; Ilkayeva O; Newgard CB; Cohen DE; Kahn CR
    J Clin Invest; 2017 Nov; 127(11):4059-4074. PubMed ID: 28972537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fructose as a key player in the development of fatty liver disease.
    Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
    World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lacking ketohexokinase-A exacerbates renal injury in streptozotocin-induced diabetic mice.
    Doke T; Ishimoto T; Hayasaki T; Ikeda S; Hasebe M; Hirayama A; Soga T; Kato N; Kosugi T; Tsuboi N; Lanaspa MA; Johnson RJ; Kadomatsu K; Maruyama S
    Metabolism; 2018 Aug; 85():161-170. PubMed ID: 29604362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone Growth is Influenced by Fructose in Adolescent Male Mice Lacking Ketohexokinase (KHK).
    Williams EAJ; Douard V; Sugimoto K; Inui H; Devime F; Zhang X; Kishida K; Ferraris RP; Fritton JC
    Calcif Tissue Int; 2020 May; 106(5):541-552. PubMed ID: 31996963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fructose consumption as a risk factor for non-alcoholic fatty liver disease.
    Ouyang X; Cirillo P; Sautin Y; McCall S; Bruchette JL; Diehl AM; Johnson RJ; Abdelmalek MF
    J Hepatol; 2008 Jun; 48(6):993-9. PubMed ID: 18395287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.